14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
TSHA vs MPLT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Taysha Gene Therapies, Inc. (TSHA) is the stronger overall head-to-head candidate over MapLight Therapeutics, Inc. (MPLT) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TSHA carries a Unified Composite Score of 49.8/100 (HOLD) at $3.72 (N/M Forward P/E, -2998.0% operating margin), whereas MPLT carries 48.3/100 (HOLD) at $5.94 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: TSHA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.7); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TSHA vs MPLT. Trailing 12-month operating profitability (TSHA -2998.0% vs MPLT 0.0%) and valuation multiples (TSHA N/M vs MPLT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $356.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ TSHA vs MPLT Key Questions & Quantitative Answers
As of Nov 20, 2026, Taysha Gene Therapies, Inc. (TSHA) is the stronger overall head-to-head candidate over MapLight Therapeutics, Inc. (MPLT) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TSHA carries a Unified Composite Score of 49.8/100 (HOLD) at $3.72 (N/M Forward P/E, -2998.0% operating margin), whereas MPLT carries 48.3/100 (HOLD) at $5.94 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: TSHA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.7); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TSHA leads the Growth & Scale pillar: TSHA posts +171.3% YoY revenue growth and +0.0% YoY earnings growth on $5.5M TTM revenue (100.0% gross margin, -2998.0% operating margin), compared with MPLT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TSHA generates $5.5M in USD-normalized revenue versus N/A for MPLT. In operating R&D and SG&A reinvestment, TSHA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MPLT.
TSHA and MPLT trade at balanced relative valuation multiples. TSHA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MPLT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TSHA (-54.2% ROE) versus MPLT (-74.2% ROE) capital efficiency.
In options market volatility and institutional positioning, TSHA carries 300.8% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.46x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 52% Vol realized risk). By comparison, MPLT carries 97.5% implied volatility (9th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.19β · 79% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.